Results 111 to 120 of about 642,453 (316)

Essential work, invisible workers: The role of digital curation in COVID‐19 Open Science

open access: yesJournal of the Association for Information Science and Technology, Volume 76, Issue 4, Page 703-717, April 2025.
Abstract In this paper, we examine the role digital curation practices and practitioners played in facilitating open science (OS) initiatives amid the COVID‐19 pandemic. In Summer 2023, we conducted a content analysis of available information regarding 50 OS initiatives that emerged—or substantially shifted their focus—between 2020 and 2022 to address ...
Irene V. Pasquetto   +2 more
wiley   +1 more source

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

Harnessing the power of artificial intelligence for disease-surveillance purposes

open access: yesBMC Proceedings
The COVID-19 pandemic accelerated the development of AI-driven tools to improve public health surveillance and outbreak management. While AI programs have shown promise in disease surveillance, they also present issues such as data privacy, prejudice ...
Barbara Tornimbene   +9 more
doaj   +1 more source

Chapter 3 Inference Based on the Diffusion Approximation of Epidemic Models

open access: yes, 2019
In the first part of these notes, several mathematical models have been proposed to describe Epidemic dynamics in a closed homogeneous community. The properties of the stochastic SEIR model have been studied in the first part of these notes.
Pardoux, Etienne   +3 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

open access: yesHepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger   +7 more
wiley   +1 more source

AN EPIDEMIC OF CHOREA [PDF]

open access: yesThe Journal of Nervous and Mental Disease, 1891
n ...
openaire   +1 more source

Epidemic Intelligence Service (EIS) 2017 annual update [PDF]

open access: yes
Bibliography (EIS Contributions to Public Health Literature: Publications with Authors in the 2014-2016 EIS Classes): p. 15-40.Epidemic Intelligence Service Program, Epidemiology Workforce Branch, Division of Scientific Education and Professional ...

core  

Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. [PDF]

open access: yes, 2009
Because of instability in eastern Afghanistan, new refugees crossed into the federally administered tribal areas of northwestern Pakistan in 2002. In 2003, we investigated an epidemic of Plasmodium falciparum malaria in 1 of the camps.
Mark Rowland   +12 more
core   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy